Onxeo S.A (CPH:ONXEO) (Paris:ONXEO), a clinical-stage biotechnology company, announced on Monday the sale of two historical products, Sitavig and Loramyc, to Vectans Pharma, a private pharmaceutical company which develops and markets therapeutics in oral pathologies.
The company said Sitavig and Loramyc are the two first products developed and registered in Europe and the US by Onxeo R&D teams for the treatment of labial herpes and oropharyngeal candidiasis.
BioAlliance Pharma SA (Paris:BIO.PA), a company dedicated to the development of orphan oncology products, announced today the execution of a licensing agreement with Innocutis Holding LLC, a pharmaceutical company dedicated to dermatology, to commercialise Sitavig in North America.
Sitavig (acyclovir Lauriad) is for the treatment of recurrent labial herpes.
Sitavig is approved in the US and eight European countries (Sweden, the UK, Spain, Italy, Denmark, Finland, Norway and Poland) for the treatment of recurrent labial herpes in adults.
According to the company, the US patent is the issuance of a third patent family in the US based on the administration scheme, a single application of Sitavig that covers the entire herpes outbreak episode.
Oncology company BioAlliance Pharma SA (Euronext Paris:BIO) said on Wednesday that it has entered into an exclusive license agreement for the commercialisation of Sitavig
's (Acyclovir Lauriad) rights in Israel.